News

Takeda Pharmaceutical Co. acquires Shire Plc. for US$62 billion and becomes the tenth biggest pharmaceutical company in the world by revenues.

Continuation of trastuzumab after an asymptomatic LVEF decline to < 50% in patients who are expected to benefit from additional anti-HER2 therapy is a promising approach that warrants further investigation – this in accordance to a study from the Dept. of Medicine of the Weill Cornell Medical College, in New York.

According to the Opti-HER HEART results, published on January 9th by the Valencian Oncology Institute (Instituto Valenciano de Oncología), the combination of dual HER2 blockade with trastuzumab and pertuzumab with paclitaxel and non-pegylated liposomal doxorubicin is associated with a low rate of cardiac events. The HER2-enriched subtype is associated with a high rate of pCR.